Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment

Naik, Raj; Kew, Fiona; Das, Nagindra; Deane, Katherine

doi:10.1002/14651858.cd006119

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5,6] The standard practice after completing primary therapy is surveillance with serial follow up of CA-125 and/or imaging. [7,8] Ovarian cancer is characterized by high frequency of P53 mutation, high somatic copy number alteration (SCNAs) and genomic instability. These data indicate a critical role of genomic instability and SCNAs in ovarian cancer prognosis and tumorigenesis.…”

Section: Introductionmentioning

confidence: 99%

Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian Cancer

Vater,

Garrett,

Collier

et al. 2023

Preprint

View full text Add to dashboard Cite

There is no routine approach to identify patients with gynecologic malignancies at high risk for chemotherapy-resistance. Circulating tumor DNA (ctDNA) tumor fraction (TFx) represents a minimally-invasive approach to tumor profiling, with as yet limited data on utility in gynecologic malignancies. The objective was to investigate the use of ctDNA TFx in a cohort of patients with ovarian and endometrial cancer. Plasma samples from patients with biopsy-proven ovarian or endometrial cancer collected between 4/2018 and 4/2020 were subjected to shallow whole genome sequencing with determination of TFx via ichorCNA package. The association of TFx to continuous and categorical baseline clinicopathologic factors and progression-free survival was assessed. 210 plasma samples from 78 patients with gynecologic cancers were analyzed. Mean TFx for ovarian cancer was 5.5% and endometrial cancer 2.4% and there was no significant difference in TFx among histology either for endometrial or ovarian cancers. Grade was associated with significant difference in ‘sentinel’ TFx among ovarian cancers but not endometrial cancers. ctDNA TFx dynamics over time demonstrated rapid clearance of ctDNA in most patients with ovarian cancer, while endometrial cancer had consistently low TFx. ctDNA TFx is feasible in ovarian and endometrial cancers and may be a valuable important tool for prognostication.

show abstract